title: Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.
abstract: 1-[4-(2-Dimethylaminoethoxy)-phenyl]-1,2-diphenylbut-1-(Z)-ene (tamoxifen, TAM) is a nonsteroidal antiestrogen that has been commonly used for the prevention and treatment of estrogen receptor-positive breast cancer. TAM is extensively metabolized into several primary active metabolites including 4-hydroxy-TAM (4-OH-TAM) and endoxifen. Glucuronidation is the major phase II metabolic pathway important in their excretion. Whereas high antiestrogenic activity has been reported for both 4-OH-TAM and endoxifen, studies examining the effect of glucuronide conjugation of these metabolites have not previously been performed. In the present study, the antiestrogenic activities of glucuronidated TAM metabolites were determined by examining their effect on the induction of the estrogen-responsive progesterone receptor (PGR) gene. 17beta-Estradiol (E(2))-mediated PGR gene expression in MCF-7 cells was determined by real-time reverse transcriptase-polymerase chain reaction for each TAM metabolite isomer. E(2) (1 x 10(-10) M) induction of PGR mRNA was 6-fold after a 12-h incubation; only unconjugated TAM metabolites inhibited this effect. A virtually identical dose-dependent inhibition of E(2)-induced PGR gene expression was found for both the trans- and cis-isomers of 4-OH-TAM and endoxifen, with maximal inhibition attained at 1 x 10(-6) M of TAM metabolite. The glucuronide conjugates of all 4-OH-TAM and endoxifen isomers exhibited no effect on E(2)-mediated induction of PGR expression at all concentrations of TAM metabolite examined in this study. These data indicate that isomers of both 4-OH-TAM and endoxifen exhibit roughly equipotent antiestrogenic effects on E(2)-induced gene expression and that glucuronide conjugates of the same metabolites effectively negate this activity. This result may have important implications in terms of both whole-body and target tissue-specific glucuronidation pathways and individual responses to TAM therapy and cancer prevention.
authors.affiliation: Cancer Prevention and Control, Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zheng
authors.forename: Dongxiao
authors.initials: D
authors.lastname: Sun
authors.forename: Arun K
authors.initials: AK
authors.lastname: Sharma
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
authors.forename: Shantu
authors.initials: S
authors.lastname: Amin
authors.forename: Philip
authors.initials: P
authors.lastname: Lazarus
mesh_terms: D045744:Cell Line, Tumor; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D020719:Glucuronides / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007536:Isomerism; D012333:RNA, Messenger / Q000378:metabolism; D011980:Receptors, Progesterone / Q000235:genetics; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D004965:Estrogen Antagonists; D020719:Glucuronides; D012333:RNA, Messenger; D011980:Receptors, Progesterone; D013629:Tamoxifen; C016601:afimoxifene; C055492:4-hydroxy-N-desmethyltamoxifen; D004958:Estradiol